Abstract
Macroautophagy (hereafter referred as to autophagy) is a vacuolar lysosomal degradative pathway for cytoplasmic macromolecules and organelles. There is growing evidence that autophagy is controlled by tumor-regulating molecules, and that it is downregulated during the early stages of tumorigenesis. Nevertheless, the relationship between autophagy and tumor progression seems to be complex, since in response to various stress situations, cancer cells are able to trigger autophagy either as a survival mechanism or conversely as a mechanism leading to cell death. Therefore, depending on the context, autophagy may trigger opposite outcomes in cancer cell fate. These two aspects of autophagy should be further taken into account in view of its possible modulation for cancer treatment.
Keywords: Autophagy, tumor, cancer therapy, apoptosis, cell death, cell survival
Current Cancer Therapy Reviews
Title: Macroautophagy as a Target of Cancer Therapy
Volume: 3 Issue: 3
Author(s): Severine Lorin, Patrice Codogno and Mojgan Djavaheri-Mergny
Affiliation:
Keywords: Autophagy, tumor, cancer therapy, apoptosis, cell death, cell survival
Abstract: Macroautophagy (hereafter referred as to autophagy) is a vacuolar lysosomal degradative pathway for cytoplasmic macromolecules and organelles. There is growing evidence that autophagy is controlled by tumor-regulating molecules, and that it is downregulated during the early stages of tumorigenesis. Nevertheless, the relationship between autophagy and tumor progression seems to be complex, since in response to various stress situations, cancer cells are able to trigger autophagy either as a survival mechanism or conversely as a mechanism leading to cell death. Therefore, depending on the context, autophagy may trigger opposite outcomes in cancer cell fate. These two aspects of autophagy should be further taken into account in view of its possible modulation for cancer treatment.
Export Options
About this article
Cite this article as:
Severine Lorin , Patrice Codogno and Mojgan Djavaheri-Mergny , Macroautophagy as a Target of Cancer Therapy, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368369
DOI https://dx.doi.org/10.2174/157339407781368369 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel 1, 2, 3-Triazole-Linked Norcantharidin Analogues: Synthesis and Evaluation of Growth Inhibition in a Panel of Selected Tumor-Cell Lines
Letters in Drug Design & Discovery PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Challenges in Breast Cancer Control in Malaysia
Current Women`s Health Reviews Cell-penetrating Peptide-mediated Nanovaccine Delivery
Current Drug Targets Exfoliated Epithelial Cells: A Non-Invasive way to Evaluate the Physiological State of Gastrointestinal Epithelium
Recent Patents on Biomedical Engineering (Discontinued) Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer
Current Cancer Drug Targets Carotenoids and Modulation of Cancer: Molecular Targets
Current Pharmacogenomics Computational Docking Studies of Novel Heterocyclic Carboxamides as Potential PI3Kα Inhibitors
Letters in Drug Design & Discovery Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
Current Cancer Drug Targets Targeting Aldose Reductase for the Treatment of Cancer
Current Cancer Drug Targets The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Patent Selections
Current Biomarkers (Discontinued) Synthesis, Anticancer Evaluation and Docking Study of 3- Benzyloxyhydantoin Derivatives
Medicinal Chemistry Radiolabelling of Ascorbic Acid: A New Clue to Clarify its Action as an Anticancer Agent?
Current Radiopharmaceuticals Diagnostic and Therapeutic Applications of Radiolabeled Somatostatin Analogs: Current Status in an Oncology Center
Current Pharmaceutical Design Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis
Current Cancer Drug Targets Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry (1→3)-α-D-Glucans from Aspergillus spp.: Structural Characterization and Biological Study on their Carboxymethylated Derivatives
Current Drug Targets